Table 1.
Clinicopathologic Characteristics of 147 HER2-Positive Breast Cancer Patients
| Variables | Number | % |
|---|---|---|
| Age (years) | ||
| ≤ 35 | 7 | 4.8 |
| > 35 | 140 | 95.2 |
| Tumor stage | ||
| T1 | 41 | 27.9 |
| T2 | 90 | 61.2 |
| T3 | 13 | 8.9 |
| T4 | 3 | 2.0 |
| Tumor differentiation | ||
| G1 | 3 | 2.0 |
| G2 | 76 | 51.7 |
| G3 | 68 | 46.3 |
| Lymph node involvement | ||
| N0 | 68 | 46.3 |
| N1 | 49 | 33.3 |
| N2 | 15 | 10.2 |
| N3 | 15 | 10.2 |
| AJCC stage | ||
| I | 33 | 22.4 |
| II | 84 | 57.2 |
| III | 30 | 20.4 |
| HR status | ||
| Positive | 62 | 42.2 |
| Negative | 85 | 57.8 |
| Ki67 | ||
| Low (≤30%) | 63 | 42.9 |
| High (>30%) | 84 | 57.1 |
| Surgery | ||
| Breast conserving surgery | 18 | 12.2 |
| Mastectomy | 129 | 87.8 |
| Radiotherapy | ||
| Yes | 87 | 59.2 |
| No | 60 | 40.8 |
| Endocrine therapy | ||
| Yes | 61 | 41.5 |
| No | 86 | 58.5 |
| NLR | ||
| ≤1.69 | 60 | 40.8 |
| >1.69 | 87 | 59.2 |
| PLR | ||
| ≤110 | 49 | 33.3 |
| >110 | 98 | 66.7 |
| SII | ||
| ≤442 | 87 | 59.2 |
| >442 | 60 | 40.8 |
Abbreviations: HER2, human epidermal growth factor receptor 2; T, tumor; N, lymph-node; AJCC, American Joint Committee on Cancer; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.